Skip to main content

Advertisement

Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Here, we synthesized two phospha sugar derivatives, 2,3,4-tribromo-3-methyl-1-phenylphospholane 1-oxide (TMPP) and 2,3-dibromo-3-methyl-1-phenylphospholane 1-oxide (DMPP) by reacting 3-methyl-1-phenyl-2-phospholene 1-oxide with bromine, and investigated their potential as antileukemic agents in cell lines. Both agents showed inhibitory effects on leukemia cell proliferation, with mean IC50 values of 6.25 μmol/L for TMPP and 23.7 μmol/L for DMPP, indicating that inhibition appeared to be dependent on the number of bromine atoms in the structure. Further, TMPP at 10 μmol/L and DMPP at 20 μmol/L induced G2/M cell cycle block in leukemia cells, and TMPP at 20 μmol/L induced apoptosis in these cells. TMPP treatment effected a reduction in both cell cycle progression signals (FoxM1, KIS, Cdc25B, Cyclin D1, Cyclin A, and Aurora-B) and tumor cell survival (p27Kip1 and p21Cip1), as well as induced the activation of caspase-3 and -9. Further, treatment with TMPP significantly reduced the viability of AML specimens derived from AML patients, but only slightly reduced the viability of normal ALDHhi progenitor cells. We also observed that FoxM1 mRNA was overexpressed in AML cells, and treatment with TMPP reduced FoxM1 mRNA expression in AML cells. Here, we report on the synthesis of TMPP and DMPP and demonstrate that these agents hinder proliferation of leukemia cells by FoxM1 suppression, which leads to G2/M cell cycle block and subsequent caspase-3-dependent apoptosis in acute leukemia cells. These agents may facilitate the development of new strategies in targeted antileukemic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

TMPP:

2,3,4-tribromo-3-methyl-1-phenylphospholane 1-oxide

DMPP:

2,3-dibromo-3-methyl-1-phenylphospholane 1-oxide

AML:

acute myeloid leukemia

ALDH:

Aldehyde Dehydrogenase

FoxM1:

The forkhead box M1

CFU-GEMM:

colony forming unit-granulocyte, erythroid, macrophage, megakaryocyte

CFU-GM:

colony forming unit-granulocyte, macrophage

BFU-E:

burst forming unit-erythroid

References

  1. Witkowski JT, Robins RK, Sidwell RW, Simon LN (1972) Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1, 2, 4-triazole-3-carboxamide and related nucleosides. J Med Chem 15:1150–1154. doi:10.1021/jm00281a014

    Article  CAS  PubMed  Google Scholar 

  2. Mitsuya H, Weinhold KJ, Furman PA, St Clair MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S (1985) 3’-Azido-3’-deoxythymidine (BW A509U); an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA 82:7096–7100. doi:10.1073/pnas.82.20.7096

    Article  CAS  PubMed  Google Scholar 

  3. McGuigan C, Pathirana RN, Balzarini J, De Clercq E (1993) Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. J Med Chem 36:1048–1052. doi:10.1021/jm00060a013

    Article  CAS  PubMed  Google Scholar 

  4. Legler G, Julich E (1984) Synthesis of 5-amino-5-deoxy-D-mannopyranose and 1, 5-dideoxy-1, 5-imino-D-mannitol, and inhibition of alpha- and beta-D-mannosidases. Carbohydr Res 128:61–72. doi:10.1016/0008-6215(84)85084-3

    Article  CAS  PubMed  Google Scholar 

  5. Takayama S, Martin R, Wu J, Laslo K, Siuzdak G, Wong CH (1997) Chemoenzymic preparation of novel cyclic imine sugars and rapid biological activity evaluation using electrospray mass spectrometry and kinetic analysis. J Am Chem Soc 119:8146–8151. doi:10.1021/ja971695f

    Article  CAS  Google Scholar 

  6. Davis BG, Maughan MA, Chapman TM, Villard R, Courtney S (2002) Novel cyclic sugar imines: carbohydrate mimics and easily elaborated scaffold for aza-sugars. Org Lett 4:103–106. doi:10.1021/ol016970o

    Article  CAS  PubMed  Google Scholar 

  7. Sinskey AJ, Barbas CF, Pederson RL, Wang YF, Wong CH (1989) Use of a recombinant bacterial fructose-1, 6-diphosphate aldolase in aldol reactions: preparative syntheses of 1-deoxynojirimycin, 1-deoxymannojirimycin, 1, 4-dideoxy-1, 4-imino-D-arabinitol, and fagomine. J Am Chem Soc 111:3924–3927. doi:10.1021/ja00193a025

    Article  Google Scholar 

  8. Braanalt J, Kvarnstroem I, Niklasson G, Svensson SCT, Classon B, Samuelsson B (1994) Synthesis of 2', 3'-Dideoxy-3'-C-(hydroxymethyl)-4'-thionucleosides as potential inhibitors of HIV. J Org Chem 59:1783–1788. doi:10.1021/jo00086a032

    Article  CAS  Google Scholar 

  9. Chmielewski M, Whistler RL (1975) 5-Thio-D-fructofuranose. J Org Chem 40:639–643. doi:10.1021/jo00893a021

    Article  CAS  Google Scholar 

  10. Wang P, Agrofoglio LA, Newton MG, Chu CK (1999) Chiral synthesis of carbocyclic analogues of L-ribofuranosides. J Org Chem 64:4173–4178. doi:10.1021/jo9812330

    Article  CAS  Google Scholar 

  11. Biggadike K, Borthwick AD, Exall AM (1990) Short convergent route to chiral pyrimidine analogs of 2'-deoxyneplanocin. Am J Chem Soc 6:458–459

    Google Scholar 

  12. Inouye S, Tsuruoka T, Ito T, Niida T (1968) Structure and synthesis of nojirimycin. Tetrahedron 24:2125–2144. doi:10.1016/0040-4020(68)88115-3

    Article  CAS  PubMed  Google Scholar 

  13. Karpas A, Fleet GW, Dwek RA, Petursson S, Namgoong SK, Ramsden NG, Jacob GS, Rademacher TW (1988) Aminosugar derivatives as potential anti-human immunodeficiency virus agents. Proc Natl Acad Sci USA 85:9229–9233. doi:10.1073/pnas.85.23.9229

    Article  CAS  PubMed  Google Scholar 

  14. Goss PE, Baker MA, Carver JP, Dennis JW (1995) Inhibitors of carbohydrate processing: a new class of anticancer agents. Clin Cancer Res 1:935–944

    CAS  PubMed  Google Scholar 

  15. Yamashita M, Nakatsukasa Y, Yoshikane M, Yoshida H, Ogata T, Inokawa S (1977) A novel method for the synthesis of sugar derivatives containing a phosphorus atom in the hemiacetal ring. Carbohydr Res 59:12–14. doi:10.1016/S0008-6215(00)83321-2

    Article  Google Scholar 

  16. Yamashita M, Nakatsukasa Y, Yoshida H, Tsunekawa K, Oshikawa T, Seo K (1979) Synthesis of 5, 6-dideoxy-3-O-methyl-5-C-(phenylphosphinyl)-D-glucopyranose and its 1, 2, 4-triacetate. Carbohydr Res 70:247–261. doi:10.1016/S0008-6215(00)87105-0

    Article  CAS  Google Scholar 

  17. Yamashita M, Yamada M, Tsunekawa K, Oshikawa T, Seo K, Inokawa S (1983) Synthesis of 5-deoxy-3-O-methyl-5-C-(phenylphosphinyl)-L-idopyranose. Carbohydr Res 121:4–5. doi:10.1016/0008-6215(83)84034-8

    Article  Google Scholar 

  18. Yamashita M, Yamada M, Sugiura M, Nomoto H, Oshikawa T (1987) Functional group interconversion of a nitro group of phosphorus compounds and synthesis of some phosphino sugars. J Chem Soc Jpn 7:1207–1213

    Google Scholar 

  19. Bennet JM, Daniel MT (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-British-American cooperative group. Ann Intern Med 103:620–625

    Google Scholar 

  20. Dimberg A, Bahram F, Karlberg I, Larsson LG, Nilsson K, Oberg F (2002) Retinoic acid-induced cell cycle arrest of human myeloid leukemia cell lines is associated with sequential down-regulation of c-Myc and cyclin E and posttranscriptional upregulation of p27 (kip1). Blood 99:2199–2206. doi:10.1182/blood.V99.6.2199

    Article  CAS  PubMed  Google Scholar 

  21. Petrovic V, Costa RH, Lau LF, Raychaudhuri P, Tyner AL (2008) FoxM1 regulates growth factor induced expression of the KIS kinase to promote cell cycle progression. J Biol Chem 104:453–460

    Google Scholar 

  22. Hess DA, Meyerrose TE, Wirthlin L, Craft TP, Herrbrich PE, Creer MH, Nolta JA (2004) Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 104:1648–1655. doi:10.1182/blood-2004-02-0448

    Article  CAS  PubMed  Google Scholar 

  23. Ye H, Holterman AX, Yoo KW, Franks RR, Costa RH (1999) Premature expression of the winged helix transcription factor HFH-11B in regenerating mouse liver accelerates hepatocyte entry into S-phase. Mol Cell Biol 19:8570–8580

    CAS  PubMed  Google Scholar 

  24. Wang X, Kiyokawa H, Dennewitz MB, Costa RH (2002) The Forkhead Box m1b transcription factor is essential for hepatocyte DNA replication and mitosis during mouse liver regeneration. Proc Natl Acad Sci USA 99:16881–16886. doi:10.1073/pnas.252570299

    Article  CAS  PubMed  Google Scholar 

  25. Korver W, Schilham MW, Moerer P, van den Hoff MJ, Dam K, Lamers WH, Medema RH, Clevers H (1998) Uncoupling of S phase and mitosis in cardiomyocytes and hepatocytes lacking the winged-helix transcription factor. Trident Curr Boil 8:1327–1330. doi:10.1016/S0960-9822(07)00563-5

    Article  CAS  Google Scholar 

  26. Laoukili J, Kooistra MR, Brás A, Kauw J, Kerkhoven RM, Morrison A, Clevers H, Medema RH (2005) FoxM1 is required for execution of the mitotic programme and chromosome stability. Nat Cell Biol 7:126–136. doi:10.1038/ncb1217

    Article  CAS  PubMed  Google Scholar 

  27. Wonsey DR, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65:5181–5189. doi:10.1158/0008-5472.CAN-04-4059

    Article  CAS  PubMed  Google Scholar 

  28. Leung TW, Lin SS, Tsang AC, Tong CS, Ching JC, Leung WY, Gimlich R, Wong GG, Yao KM (2001) Over-expression of FoxM1 stimulates cyclin B1 expression. FEBS Lett 507:59–66. doi:10.1016/S0014-5793(01)02915-5

    Article  CAS  PubMed  Google Scholar 

  29. Yokozawa T, Towatari M, Iida H, Takeyama K, Tanimoto M, Kiyoi H, Motoji T, Asou N, Saito K, Takeuchi M, Kobayashi Y, Miyawaki S, Kodera Y, Ohno R, Saito H, Naoe T (2000) Prognostic significance of the cell cycle inhibitor p27Kip1 in acute myeloid leukemia. Leukemia 14:28–33. doi:10.1038/sj.leu.2401640

    Article  CAS  PubMed  Google Scholar 

  30. Wonsey D, Follettie MT (2005) Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res 65:5181–5189. doi:10.1158/0008-5472.CAN-04-4059

    Article  CAS  PubMed  Google Scholar 

  31. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B (1998) Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282:1497–1501. doi:10.1126/science.282.5393.1497

    Article  CAS  PubMed  Google Scholar 

  32. Williams ME, Swerdlow SH, Rosenberg CL, Arnold A (1993) Chromosome 11 translocation breakpoints at the PRAD1/cyclin D1 gene locus in centrocytic lymphoma. Leukemia 7:241–245

    CAS  PubMed  Google Scholar 

  33. Zhang H, Kobayashi R, Galaktionov K, Beach D (1995) p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. Cell 82:915–925. doi:10.1016/0092-8674(95)90271-6

    Article  CAS  PubMed  Google Scholar 

  34. Ikezoe T, Yang J, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H (2007) A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia. Mol Cancer Ther 6:1851–1859. doi:10.1158/1535-7163.MCT-07-0067

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This study was supported by Ministry of Education, Culture, Sports Science and Technology of Japan, Aid for Scientific Research (#17590987).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Satoki Nakamura.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakamura, S., Yamashita, M., Yokota, D. et al. Development and pharmacologic characterization of deoxybromophospha sugar derivatives with antileukemic activity. Invest New Drugs 28, 381–391 (2010). https://doi.org/10.1007/s10637-009-9255-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-009-9255-3

Keywords